Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of zanamivir in preparation of medicine for treating or preventing preeclampsia

A technology for zanamivir and preeclampsia is applied in the field of use of zanamivir in the preparation of drugs for treating or preventing preeclampsia, and can solve the problems of lack of treatment means, unclear pathogenesis and the like

Pending Publication Date: 2022-05-27
SHENZHEN EVERGREEN THERAPEUTICS CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although there are a large number of preclinical and clinical studies on preeclampsia, its pathogenesis is known to be complex but still unclear, and corresponding treatment methods are also quite scarce. Generally, only symptomatic blood pressure lowering, diuretic, and sedative treatments are used. Severe eclampsia occurs Magnesium sulfate can be used to relieve spasms, and termination of pregnancy is still the most effective clinical treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of zanamivir in preparation of medicine for treating or preventing preeclampsia
  • Application of zanamivir in preparation of medicine for treating or preventing preeclampsia
  • Application of zanamivir in preparation of medicine for treating or preventing preeclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Establishment of an animal model of preeclampsia

[0058] Pregnant CD-1 mice (aged 8-10 weeks) were randomly divided into control group and preeclampsia model group. On days 7-16 of the gestational cycle, preeclampsia was induced in mice in the model group by subcutaneous injection of 50 mg / kg of N-nitro-L-arginine methyl ester (L-NAME) every day. In the control group, an equal volume of solvent was injected subcutaneously.

Embodiment 2

[0059] Example 2 Experimental grouping

[0060]

[0061]

Embodiment 3

[0062] Example 3 Evaluation of therapeutic effect

[0063] In L-NAME-induced preeclampsia animal models, according to literature reports, symptoms of hypertension appear two days after the first administration of L-NAME, and persist until at least five days after the first administration of L-NAME. Symptoms of proteinuria appear relatively late. Therefore, in this experiment, we focused on monitoring blood pressure changes in pregnant mice on the 12th day of pregnancy (that is, five days after the first administration of L-NAME), as well as collecting 24-hour urine on the 17th-18th day of pregnancy and measuring the level of total protein . At the same time, we also recorded the number of pups produced by each group of pregnant mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of zanamivir in preparation of a medicine for treating or preventing preeclampsia, a corresponding medicine and a treatment method. Zanamivir can effectively improve the symptoms of hypertension, proteinuria, creatinine, neuraminidase and sialic acid rise of preeclampsia and increase the NO level; the pregnancy outcome is improved. The combination of zanamivir and hydroxyprogesterone hexanoate shows a better effect.

Description

technical field [0001] The present application provides the use of zanamivir in the preparation of a medicine for treating or preventing preeclampsia, as well as the corresponding medicine and treatment method. Background technique [0002] Preeclampsia, also known as preeclampsia or toxemia of pregnancy, refers to the clinical symptoms of hypertension, proteinuria and edema that appear after 20 weeks of pregnancy, accompanied by headache, vertigo, nausea, vomiting, abdominal discomfort, etc. syndrome. Preeclampsia not only affects the development of the fetus, but often endangers the life of the mother. The pathophysiological process of the disease is roughly divided into two stages: 1) Abnormal placenta formation, especially uterine spiral arteriole diastolic disorder, which affects the blood supply from the mother to the fetus. Reduced placental perfusion activates placental release of associated cytokines and causes systemic hemodynamic changes. 2) Clinical symptoms i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/351A61K45/06A61K31/57A61P15/00A61P9/12A61P13/00A61P7/10A61P25/00A61P27/02A61P1/08A61P1/00
CPCA61K31/351A61K45/06A61K31/57A61P15/00A61P9/12A61P13/00A61P7/10A61P25/00A61P27/02A61P1/08A61P1/00A61K2300/00A61K31/7012
Inventor 杜涛胡涛杜新
Owner SHENZHEN EVERGREEN THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com